Zhi Tong Cai Jing·2025-08-26 13:19Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) announced a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huicheng Pharmaceutical Co., Ltd. (Sichuan Huicheng), which is a wholly-owned subsidiary of Sichuan Huicheng [1] Group 1 - Sichuan Huicheng's board approved the potential agency agreement for TY-9591, which will allow Sichuan Huicheng to act as the exclusive agent in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and if the agency arrangement is finalized, it will leverage Sichuan Huicheng's extensive sales and distribution network [1] Group 2 - Sichuan Huicheng is a mature pharmaceutical enterprise with a complete industry chain and rich experience in drug agency and sales in China [1] - The company believes that this arrangement will enhance the sales and revenue of TY-9591, accelerate market penetration, reduce costs associated with establishing new sales channels, and strengthen its brand image through collaboration with a well-known pharmaceutical company [1]